Capital Analysts LLC’s Biogen BIIB Stock Holding History

Capital Analysts LLC’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$92K	Hold	501	–	–	﹤0.01%	814
2025 Q4	$88K	Hold	501	–	–	﹤0.01%	792
2025 Q3	$70K	Hold	501	–	–	﹤0.01%	813
2025 Q2	$63K	Hold	501	–	–	﹤0.01%	762
2025 Q1	$69K	Hold	501	–	–	﹤0.01%	724
2024 Q4	$77K	Sell	501 -15	-3%	-$2.53K	﹤0.01%	669
2024 Q3	$100K	Hold	516	–	–	﹤0.01%	584
2024 Q2	$120K	Hold	516	–	–	0.01%	536
2024 Q1	$111K	Hold	516	–	–	0.01%	531
2023 Q4	$134K	Hold	516	–	–	0.01%	485
2023 Q3	$133K	Hold	516	–	–	0.01%	447
2023 Q2	$147K	Hold	516	–	–	0.01%	410
2023 Q1	$143K	Sell	516 -285	-36%	-$78.9K	0.01%	416
2022 Q4	$222K	Hold	801	–	–	0.01%	385
2022 Q3	$214K	Hold	801	–	–	0.01%	346
2022 Q2	$163K	Hold	801	–	–	0.01%	364
2022 Q1	$169K	Hold	801	–	–	0.01%	357
2021 Q4	$192K	Hold	801	–	–	0.01%	344
2021 Q3	$227K	Hold	801	–	–	0.01%	326
2021 Q2	$277K	Hold	801	–	–	0.02%	306
2021 Q1	$224K	Buy	801 +285	+55%	+$76.9K	0.02%	321
2020 Q4	$126K	Hold	516	–	–	0.01%	283
2020 Q3	$146K	Hold	516	–	–	0.01%	273
2020 Q2	$138K	Sell	516 -120	-19%	-$36.1K	0.01%	247
2020 Q1	$201K	Sell	636 -246	-28%	-$74.7K	0.02%	206
2019 Q4	$262K	Buy	882 +103	+13%	+$28.6K	0.03%	220
2019 Q3	$181K	Sell	779 -46	-6%	-$10.7K	0.02%	229
2019 Q2	$193K	Sell	825 -96	-10%	-$22.2K	0.02%	222
2019 Q1	$217K	Buy	921 +237	+35%	+$74.6K	0.03%	210
2018 Q4	$206K	Buy	684 +119	+21%	+$38K	0.03%	196
2018 Q3	$200K	Buy	565 +72	+15%	+$24.8K	0.02%	191
2018 Q2	$143K	Hold	493	–	–	0.02%	217
2018 Q1	$135K	Buy	493 +106	+27%	+$32.9K	0.02%	209
2017 Q4	$123K	Hold	387	–	–	0.02%	216
2017 Q3	$121K	Hold	387	–	–	0.02%	219
2017 Q2	$105K	Hold	387	–	–	0.02%	231
2017 Q1	$106K	Sell	387 -36	-9%	-$10.2K	0.02%	205
2016 Q4	$120K	Buy	423 +6	+1%	+$1.78K	0.02%	206
2016 Q3	$131K	Hold	417	–	–	0.02%	191
2016 Q2	$101K	Sell	417 -10,747	-96%	-$2.83M	0.02%	206
2016 Q1	$2.91M	Buy	11,164 +373	+3%	+$98.5K	0.58%	40
2015 Q4	$3.31M	Buy	10,791 +10,397	+2,639%	+$2.99M	0.67%	29
2015 Q3	$115K	Buy	+394	New	+$130K	0.02%	218

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Analysts LLC's BIIB Position: Q1 2026 in Review

Capital Analysts LLC held its Biogen (BIIB) position steady in Q1 2026 at 501 shares worth $92K. The position accounts for ﹤0.01% of the portfolio, ranked #814.

Capital Analysts LLC first reported a position in BIIB in Q3 2015 and has held it in 43 quarters since. The position peaked at $3.31M in Q4 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Capital Analysts LLC held 501 shares of Biogen worth $92K as of Q1 2026.
Capital Analysts LLC left its Biogen share count unchanged in Q1 2026.
Biogen made up ﹤0.01% of Capital Analysts LLC's portfolio in Q1 2026, its #814 holding.
Capital Analysts LLC first reported a position in Biogen in Q3 2015 and has held it in 43 quarters since.
Capital Analysts LLC's Biogen position peaked at $3.31M in Q4 2015.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Capital Analysts LLC's 13F filing for Q1 2026, filed 14 May 2026.